Evan M. Sisson

700 total citations
34 papers, 497 citations indexed

About

Evan M. Sisson is a scholar working on Geriatrics and Gerontology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Evan M. Sisson has authored 34 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Geriatrics and Gerontology, 16 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Surgery. Recurrent topics in Evan M. Sisson's work include Pharmaceutical Practices and Patient Outcomes (16 papers), Diabetes Treatment and Management (9 papers) and Blood Pressure and Hypertension Studies (8 papers). Evan M. Sisson is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (16 papers), Diabetes Treatment and Management (9 papers) and Blood Pressure and Hypertension Studies (8 papers). Evan M. Sisson collaborates with scholars based in United States, Switzerland and Latvia. Evan M. Sisson's co-authors include Dave L. Dixon, John D. Bucheit, Kevin J. Malloy, Nicole Carter, Teresa M. Salgado, Benjamín Van Tassell, Vimal Mishra, Daniel Carl, Pramit Nadpara and Alan Dow and has published in prestigious journals such as Journal of the American College of Cardiology, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy and Journal of Cardiovascular Pharmacology.

In The Last Decade

Evan M. Sisson

29 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evan M. Sisson United States 13 196 126 104 96 69 34 497
Brian K. Irons United States 13 228 1.2× 106 0.8× 150 1.4× 60 0.6× 65 0.9× 34 580
Márcia Silva Queiroz Brazil 15 314 1.6× 166 1.3× 44 0.4× 108 1.1× 57 0.8× 39 784
Krishna Undela India 15 96 0.5× 214 1.7× 55 0.5× 252 2.6× 23 0.3× 48 865
Mafauzy Mohamed Malaysia 17 610 3.1× 113 0.9× 25 0.2× 103 1.1× 56 0.8× 54 954
Shannon Miller United States 11 215 1.1× 111 0.9× 39 0.4× 96 1.0× 25 0.4× 25 444
Sarah Woolsey Canada 10 128 0.7× 107 0.8× 27 0.3× 75 0.8× 98 1.4× 15 501
Jaekyu Shin United States 14 88 0.4× 171 1.4× 25 0.2× 56 0.6× 39 0.6× 43 728
Phil Mendys United States 12 100 0.5× 166 1.3× 151 1.5× 130 1.4× 122 1.8× 19 933
Harry Glauber United States 17 590 3.0× 198 1.6× 26 0.3× 221 2.3× 61 0.9× 22 1.1k
Samantha Karr United States 5 55 0.3× 80 0.6× 26 0.3× 94 1.0× 42 0.6× 10 558

Countries citing papers authored by Evan M. Sisson

Since Specialization
Citations

This map shows the geographic impact of Evan M. Sisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan M. Sisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan M. Sisson more than expected).

Fields of papers citing papers by Evan M. Sisson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan M. Sisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan M. Sisson. The network helps show where Evan M. Sisson may publish in the future.

Co-authorship network of co-authors of Evan M. Sisson

This figure shows the co-authorship network connecting the top 25 collaborators of Evan M. Sisson. A scholar is included among the top collaborators of Evan M. Sisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan M. Sisson. Evan M. Sisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sisson, Evan M., et al.. (2025). Implementation of a continuous glucose monitoring workflow in a complex primary care clinic. Journal of the American Association of Nurse Practitioners. 38(1). 38–46.
2.
3.
Procaccini, M, et al.. (2024). Using insulin pump for glycemic control in patients with severe insulin resistance. Journal of the American Pharmacists Association. 64(2). 588–591.
4.
Salgado, Teresa M., et al.. (2023). Job satisfaction among board-certified pharmacists in Virginia. Journal of the American Pharmacists Association. 64(1). 126–132. 2 indexed citations
5.
Talasaz, Azita H., Anurag Mehta, Michael S. Kelly, et al.. (2023). Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 43(10). 1051–1063. 21 indexed citations
6.
Sisson, Evan M., et al.. (2022). Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery. Journal of the American Pharmacists Association. 62(5). 1581–1586. 3 indexed citations
7.
Bucheit, John D., et al.. (2022). A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. Journal of Cardiovascular Pharmacology. 80(2). 171–179. 9 indexed citations
8.
Dixon, Dave L., et al.. (2021). An ounce of prevention is worth a pound of cure: considerations for pharmacists delivering the National Diabetes Prevention Program. Pharmacy Practice. 19(2). 2426–2426. 3 indexed citations
9.
10.
Dixon, Dave L., et al.. (2019). Impact of a pharmacist‐physician collaborative care model on time‐in‐therapeutic blood pressure range in patients with hypertension. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 3(2). 404–409. 8 indexed citations
11.
Bucheit, John D., et al.. (2019). Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Diabetes Technology & Therapeutics. 22(1). 10–18. 106 indexed citations
12.
Dixon, Dave L., Evan M. Sisson, Benjamín Van Tassell, et al.. (2017). Pharmacist‐physician collaborative care model and time to goal blood pressure in the uninsured population. Journal of Clinical Hypertension. 20(1). 88–95. 25 indexed citations
13.
Dixon, Dave L., et al.. (2017). Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. Pharmacy Practice. 15(4). 1134–1134. 47 indexed citations
14.
Sisson, Evan M., et al.. (2017). Evolving Role of Non‐Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 38(2). 164–171. 6 indexed citations
15.
Dixon, Dave L., Evan M. Sisson, Benjamín Van Tassell, et al.. (2017). COMPARISON OF A PHARMACIST-PHYSICIAN COLLABORATIVE CARE MODEL TO STANDARD CARE ON THE TIME TO REACH GOAL BLOOD PRESSURE FOR PATIENTS PRESENTING WITH URGENT HYPERTENSION. Journal of the American College of Cardiology. 69(11). 1837–1837. 1 indexed citations
16.
Kelly, Michael S., Craig J. Beavers, John D. Bucheit, Evan M. Sisson, & Dave L. Dixon. (2017). Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150–499 mg/dL). Journal of clinical lipidology. 11(4). 872–879. 7 indexed citations
17.
Dixon, Dave L., et al.. (2013). Lomitapide and Mipomersen. The Journal of Cardiovascular Nursing. 29(5). E7–E12. 17 indexed citations
18.
Sisson, Evan M.. (2011). Liraglutide: Clinical Pharmacology and Considerations for Therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 31(9). 896–911. 37 indexed citations
19.
Sisson, Evan M., et al.. (2009). Pharmacist roles in the management of patients with type 2 diabetes. Journal of the American Pharmacists Association. 49(5). S41–S45. 27 indexed citations
20.
Campbell, R. Keith, et al.. (2009). Type 2 diabetes: Epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist. Journal of the American Pharmacists Association. 49(5). S2–S2. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian K. Irons Breakdown of academic impact, for papers by Márcia Silva Queiroz Breakdown of academic impact, for papers by Krishna Undela Breakdown of academic impact, for papers by Mafauzy Mohamed Breakdown of academic impact, for papers by Shannon Miller Breakdown of academic impact, for papers by Sarah Woolsey Breakdown of academic impact, for papers by Jaekyu Shin Breakdown of academic impact, for papers by Phil Mendys Breakdown of academic impact, for papers by Harry Glauber Breakdown of academic impact, for papers by Samantha Karr
Rankless by CCL
2026